Recognising unsung care heroes
These experts play a pivotal role in delivering patient-centred care, ensuring that patients receive comprehensive services, from diagnosis to recovery and rehabilitation.
Who Are AHP?
AHP encompass a wide range of specialists such as medical laboratory scientist, physiotherapists, radiographers, dietitians, occupational therapists, speech-language pathologists and many more.
They provide essential services in diagnostics, rehabilitation, therapeutic services and prevention. Whether they help patients regain mobility after an accident or diagnose complex conditions using cutting-edge technology, AHP are integral to healthcare delivery.
AHP are the backbone of sustainable rehabilitative care. Their role goes far beyond diagnosis or acute hospital care. They are essential to a holistic, people-centred approach that begins before diagnosis and continues through recovery, especially within primary health care and community-based settings.
Impact of AHP
AHP perform crucial tasks that directly impact patient outcomes. For instance, radiographers use imaging technologies like X-rays and MRIs to provide the data doctors rely on for critical decisions.
Clinical laboratory technologists analyse blood samples, providing essential information for treatment plans. Rehabilitation services further highlight AHP's contributions.
Physiotherapists help patients recover mobility after surgery or injury while occupational therapists promote independence in everyday activities.
During the Covid-19 pandemic, respiratory therapists and laboratory technologists were instrumental in managing ventilators and processing test samples, ensuring timely, life-saving care.
Addressing need for recognition and resources
Despite their vital role, AHP's efforts often go unseen. The Allied Health Professions Act 2016 (Act 774) addresses the registration of individuals practising as AHP, elevating them in Malaysia.
However, beyond registration, greater recognition and investment in AHP are essential for their continued contribution to the healthcare sector.
Recognising the contributions of AHP is essential to raising public awareness, showcasing their value and creating greater opportunities for professional growth and recognition.
One way to enhance visibility is by incorporating AHP into national healthcare policies, ensuring their roles are acknowledged in workforce planning and service delivery models.
Additionally, public awareness campaigns can educate communities on the services that AHP provide, fostering appreciation for their work.
Establishing recognition programmes, such as national awards or career advancement pathways, can also motivate and retain talent within the profession.
In terms of resources, more efforts should be made to expand educational opportunities for aspiring AHP.
Universities and training institutions should be encouraged to offer specialised AHP programmes, ensuring a steady pipeline of skilled professionals.
Moreover, increasing access to continuous professional development courses, workshops and certification programmes will enable AHP to stay updated with the latest advancements in their fields.
Innovators in healthcare
AHP are more than just support staff, they are innovators driving advancements in healthcare in a multidisciplinary team.
Their expertise in adopting new diagnostic tools and therapeutic techniques help enhance service delivery and improve patient outcomes. Public-private partnerships play a key role in transforming healthcare systems.
Meeting the human capacity needs of the AHP is not something we can do alone; it requires strong partnerships. Collaboration between academia, the government and private sectors is vital.
From diagnosis to rehabilitation, the contributions of AHP are essential in patient care.
As healthcare continue to evolve, it is crucial to recognise and support these professionals who ensure that every patient receives comprehensive, high-quality care.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 hours ago
- The Star
Penang sisters find success with Himalayan fruit
JOHOR BARU: A family of six sisters, who wanted to help some villages in a remote part of the Himalayas, are now sourcing a powerful fruit that is used to produce vegan skincare products. Lay Kim Onn, said the venture into the health and beauty business was a coincidence, as four of the sisters had travelled to the Himalayas in 2012 in search of a Buddhist monk who was carrying out social work and helping a rural community there. 'We all grew up in an average family in Penang where we were trained from young to give a portion of our earnings to help the poor. 'All six sisters were graduates holding important positions in healthcare and the corporate world. 'So we wanted to donate the RM10,000 we had collected to this charity organisation in the Himalayas,' said Lay Kim, who is the second child in the family. She said that during their visit, they discovered a fruit known as the Himalayan Apricot, which grows at about 4,500m above sea level. 'This hardy plant is harvested by the women in the villages, who then turn the fruit into oil that is applied on the skin daily,' she said, adding that they noticed the villagers had good skin complexions despite not using any sunscreen, even with the high levels of ultraviolet (UV) rays due to the altitude. She said most of the villagers were very poor, and excess apricots were used to feed livestock. 'We realised its medicinal potential, and in 2013, I decided to carry out more research, including enrolling in a four-year course in organic cosmetic science,' she said, adding that in 2015, they all chipped in some capital and decided to start their company, Onn Natural Enterprise Sdn Bhd (Idemo). She said that the sisters, who started off working part-time in Idemo, took up different roles in the company, and she was in charge of research and development. 'We continued purchasing apricot kernels from the villages for our research, and in fact, we only started marketing our product this year after obtaining all the necessary certifications. 'Earlier, we were carrying out research, and for three years during the Covid-19 pandemic, we had to stop to care for our ailing mother,' she said, adding that their skin cream helped with their mother's bedsores and promoted a healthy complexion. Lay Kim said they now have a factory in Penang and have diversified from one product to seven, comprising oils, creams, and gels. 'This year, we also won two awards, – Best Vegan Natural Skincare Brand 2025 and the Beauty Shortlist Awards 2025 – Britain,' she said. Their products are currently being exported to the Middle East, Europe, and Indonesia and they now plan to attract more investors to expand production and market their products in China and across Malaysia.
The Star
a day ago
- The Star
New hospital to open next month
Hospital Pasir Gudang is expected to reduce the patient load at two Johor Baru hospitals. AFTER a five-year wait, Johor's Hospital Pasir Gudang (HPG) is set to open in phases starting next month. Johor health and environment committee chairman Ling Tian Soon said the RM380mil hospital would begin operations by running its emergency and trauma department and general surgery department. 'The rest of the 304-bed hospital will open up in stages. 'Once fully operational next year, the hospital will have 14 specialist clinics. 'We want to ensure that all the specialist clinics are ready with the respective specialist doctors, medical team and equipment before taking in patients.' Ling said the hospital had appointed people to key positions such as director and deputy directors and was in the process of filling more than 1,800 vacancies as approved by the Health Ministry. So far, over 270 positions had been filled, he said, adding that more vacancies would be filled by August. He said the state government had asked the ministry to station doctors and nurses at HPG or transfer them from other existing healthcare facilities, and this would take time. Ling said construction for the hospital began in 2020 but there were significant setbacks due to the Covid-19 pandemic and movement restrictions. The hospital was completed earlier this year. At full capacity, HPG is expected to cater to 900,000 residents in Pasir Gudang and its surrounding areas. It is also expected to reduce the patient volume at Hospital Sultanah Aminah (HSA) and Hospital Sultan Ismail, both located in Johor Baru. Ling said the ministry was preparing a proposal for another major healthcare project in Johor – the construction of a 1,500-bed HSA 2 near Universiti Teknologi Malaysia, Skudai. 'The proposal will be handed over to the Public Private Partnership Unit hopefully by this month, for it to be brought to the Cabinet to discuss its implementation. 'The land matters have been sorted out and technical workshops have also been held to look into what is needed for HSA 2. 'We have another major project at the existing HSA, which is to add a new building called Ambulatory Care Centre, so we want to make sure there are no conflicts between both projects.' Previously, Ling reportedly said the HSA 2 project was to begin development in 2026 with a public-private partnership model as announced by Prime Minister Datuk Seri Anwar Ibrahim in his Budget 2025 speech. HSA 2 will be built on a 28.33ha land provided by the Defence Ministry from a 202.34ha site, making it the largest hospital in Johor.
Malaysian Reserve
a day ago
- Malaysian Reserve
First Lung Organoid with Organ-Specific Blood Vessels
Advanced lab-grown tissues help show how special lung cells develop, shedding light on rare ACDMPV disease and suggesting potential ways to repair damage from viral infections such as COVID-19 CINCINNATI, June 30, 2025 /PRNewswire/ — A team of experts at Cincinnati Children's reports another powerful step forward in organoid medicine: success at making human lung tissue that can produce its own blood vessels. Their findings, published in the same month as a similar success involving liver organoids, reflect a new wave of advanced lab-grown tissues that can be used immediately in many research applications while moving ever closer to serving as living tissues that can directly repair damaged organs. Details were posted online June 30, 2025, in the journal Cell. 'Prior to our study, the development of lung organoids with organotypic vasculature had not been achieved,' says co-corresponding author Mingxia Gu, MD, PhD. 'Notably, this method also could be applied to other organ systems such as intestine and colon.' Gu, now at UCLA, was a member of the Center for Stem Cell and Organoid Medicine (CuSTOM) and Division of Pulmonary Biology at Cincinnati Children's while this research was conducted. Co-first and co-corresponding author Yifei Miao, PhD, (now at the Chinese Academy of Sciences, Beijing) also was with Cincinnati Children's for this work. Co-corresponding author Minzhe Guo, PhD, remains with Cincinnati Children's along with several co-authors involved in this study. Overcoming a major challenge Researchers have been working for years to grow organoids — sometimes called 'organs in a dish.' Creating organoids involves converting mature human cells (such as blood or tissue cells) back into fetal-like stem cells that can be coaxed into growing a wide range of other tissue types. Unlike disconnected human cells kept alive in a dish, these are growing, developing mini-organs that form into seed-sized spheres that mimic the unique functions of full-sized organs. Intestines that absorb and secrete. Stomachs that produce digestive acids. Hearts that pulse. Brain tissues with firing nerve cells and so on. Cincinnati Children's has been a leader in organoid development since 2010 when experts here produced the world's first functional intestinal organoid grown from induced pluripotent stem cells (iPSCs). More recently, the challenge has been learning how to grow organoid tissues that can connect with the rest of the body to integrate nerve connections, blood vessels, bile ducts, immune systems and more. During pregnancy, these differing tissue types naturally find each other as the fetus matures and becomes more complex. Organoid developers seek to re-produce these steps in the laboratory, which eventually may allow people to receive custom-grown tissues that could patch damage or boost disrupted functions. Simpler forms of organoids have already begun transforming medical research, allowing many scientists to use living human tissue models to study disease while reducing current reliance on animal models to develop new medicines. But without the ability to make internal blood vessels, the tiny seeds lack the ability to grow into larger, more useful tissues. How the team solved the vascular riddle The new study thoroughly recounts the results of many experiments the team conducted to demonstrate success at inducing blood vessel formation. The work spanned four years and involved more than 20 people at Cincinnati Children's plus collaborations with experts at several other organizations. 'The challenge in vascularizing endodermal organs, particularly the lung, stems from different signaling requirements for lung epithelial versus vascular differentiation,' says Miao. 'Our success in this endeavor is attributable to our unique differentiation method.' In essence, the team grew iPSCs from multiple cell types then found the right moment to introduce them to each other. The resulting cell signals helped flip a developmental switch so that progenitor cells that could have become either blood vessels or the outer walls of the lung wound up becoming blood vessels. In achieving this vital step, the team: Produced lung organoids that include respiratory bronchial epithelial cells (RAS cells), a human cell type not previously reported in conventional lung organoid models. Pinned down the developmental moments when a rudimentary gut tube begins to send some cells to form the lungs while sending other cells to form the stomach and intestine. While the basic steps of this transformation have been studied in animals, it had not been possible to study this stage of development in humans without killing fetuses. Demonstrated that the rare disease ACDMPV occurs when cell signaling 'crosstalk' gets disrupted during this early blood vessel formation stage. Within days of birth, infants born with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) struggle to breathe because their lungs' air sacs (alveoli) and blood vessels are malformed. Nearly all infants with this condition die within the first month of life, according to the National Organization for Rare Disorders. Revealed key functional information about the cells involved in gas exchange inside the human lung. Their learnings help explain the damage within tiny blood capillaries that occurs in the lungs in response to injuries. These new clues offer fresh ideas for developing ways to protect and potentially restore affected lung tissues. What's Next? Cincinnati Children's has filed patent applications related to the methods developed here to produce organoids with blood vessel formation capabilities and the CuSTOM team is moving to further develop this technology. 'We look forward to continuing to learn more about the fundamental biology involved in organ formation and applying those discoveries to improving outcomes across a wide range of difficult human diseases and conditions,' says Aaron Zorn, PhD, co-director of CuSTOM and director of the Division of Developmental Biology. In addition to publishing these findings in Cell, co-authors plan to present their work at the Keystone conference in Kyoto, Japan (iPSCs: Progress, Opportunities, and Challenges) in January 2026. About the study Cincinnati Children's co-equal first authors were Miao, Nicole Pek, BS, and Cheng Tan, MD. Contributing co-authors from Cincinnati Children's were Cheng Jiang, MS, Zhiyun Yu, PhD, Kentaro Iwasawa, MD, PhD, Min Shi, MD, PhD, Daniel Kechele, PhD, Nambirajan Sundaram, PhD, Victor Pastrana-Gomez, MSTP student, Debora Sinner, PhD, Cheng-Lun Na, PhD, Keishi Kishimoto, PhD, Jason Tchieu, PhD, Jeffrey Whitsett, MD, Kyle McCracken, MD, PhD, Michael Helmrath, MD, James Wells, PhD, Takanori Takebe, MD, PhD, and Aaron Zorn, PhD. Contributing co-authors included experts from Harvard Medical School, Icahn School of Medicine at Mount Sinai, Sophia Children's Hospital (The Netherlands), Boston University This research also was supported by the Discover Together Biobank, the Bio-Imaging and Analysis Facility, and the Integrated Pathology Research Core at Cincinnati Children's and the University of Cincinnati Proteomics Laboratory. Funding sources for this work included: the National Institutes of Health (R01HL166283, DK128799-01, N01-75N92020C00005 and R01HL095993); an Endowed Scholar Award from the Cincinnati Children's Research Foundation; the American Heart Association (1013861 and 906513); the Falk Transformational Awards Program; and the Brigham Research Institute. Learn more about working with CuSTOM Learn how donors can support ongoing organoid research at Cincinnati Children's
